04.01.2014 Views

Broker-Dealer Litigation - Greenberg Traurig LLP

Broker-Dealer Litigation - Greenberg Traurig LLP

Broker-Dealer Litigation - Greenberg Traurig LLP

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

D.1<br />

White v. Kolinsky, 2011 WL 1899307 (D.N.J. May 18, 2011).<br />

Investors brought suit against defendants for alleged violations of federal securities laws<br />

and defendants moved to dismiss for failure to state a claim as required under the heightened<br />

pleading standard of the PSLRA. Plaintiffs alleged that defendants knew of prior costs already<br />

incurred prior to soliciting investment from plaintiffs and failed to disclose those costs as well as<br />

other potential financing hurdles the investment project was experiencing. The court granted<br />

defendants’ motion to dismiss finding that plaintiffs’ allegations rested on inadequately<br />

particularized “group pleading” claims which were not permitted under the PSLRA. The court,<br />

however, denied the other defendants motion to dismiss finding that whether many of the<br />

statements contained in a private offering memorandum were actionable was a question of fact.<br />

In re Merck & Co., Inc. Sec., Derivative, & ERISA Litig., 2011 WL 3444199 (D.N.J. Aug. 8,<br />

2011).<br />

Plaintiffs brought a class action suit against defendant pharmaceutical company for<br />

violations of federal securities laws and defendants filed motion to dismiss for failure to state a<br />

claim as required under the heightened pleading standards of the PSLRA. Plaintiffs alleged that<br />

defendant overstated the commercial viability of one of their drugs or at least recklessly<br />

downplayed the possible link between the drug and cardiovascular complications. Plaintiffs<br />

claimed that the company had strong evidence of heart-attack link with the drug even before the<br />

product launched. Plaintiffs alleged that this evidence continued to increase while company<br />

continued to tout its safety on the market. The court granted defendants’ motion to dismiss with<br />

respect to the alleged misrepresentations of all defendants except for one.<br />

In re Anadigics, Inc., Securities <strong>Litigation</strong>, 2011 WL 4594845 (D.N.J. Sept. 30, 2011).<br />

Plaintiffs brought suit against defendants alleging violations of federal securities laws and<br />

defendants moved to dismiss for failure to state a claim under the heightened pleading<br />

requirements of the PSLRA. Plaintiffs alleged defendants misled investors about its capability to<br />

meet demand for its products. The court granted defendants’ motion to dismiss holding that the<br />

allegedly false or misleading statements were not actionable because they had not been pleaded<br />

with the requisite particularity as to either falsity or scienter. Specifically, the court found that<br />

statements regarding supply shortages no longer being a concern and demand no longer<br />

outstripped capacity to be pleaded with the requisite particularity. The court held, however, that<br />

plaintiff failed to allege any facts with regard to those statements from which the court could<br />

infer scienter.<br />

D.1<br />

D.1<br />

148

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!